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Abstract
Introduction: This survey was initiated to obtain knowledge on the current situation of internal quality control (IQC) practice for tumour markers 
(TMs) in China. Additionally, we tried to acquire the most appropriate quality specifications.
Materials and methods: This survey was a current status survey. The IQC information had been collected via online questionnaires. All of 1821 cli-
nical laboratories which participated in the 2016 TMs external quality assessment (EQA) programme had been enrolled. The imprecision evaluation 
criteria were the minimal, desirable, and optimal allowable imprecisions based on biological variations, and 1/3 total allowable error (TEa) and 1/4 
TEa.
Results: A total of 1628 laboratories answered the questionnaires (89%). The coefficients of variation (CVs) of the IQC of participant laboratories 
varied greatly from 1% (5th percentile) to 13% (95th percentile). More than 82% (82 - 91%) of participant laboratories two types of CVs met 1/3 TEa 
except for CA 19-9. The percentiles of current CVs were smaller than cumulative CVs. A number of 1240 laboratories (76%) reported their principles 
and systems used. The electrochemiluminescence was the most used principle (45%) and had the smallest CVs.
Conclusions: The performance of laboratories for TMs IQC has yet to be improved. On the basis of the obtained results, 1/3 TEa would be realistic 
and attainable quality specification for TMs IQC for clinical laboratories in China.
Key words: internal quality control; tumour marker; imprecision; biological variation
Received: September 10, 2017 Accepted: January 21, 2018
Original papers
https://doi.org/10.11613/BM.2018.020702 Biochem Med (Zagreb) 2018;28(2):020702 
 1
Introduction
Although the diagnosis of cancer is mostly con-
firmed by biopsy which has been considered as 
“gold standard” for a long time, tumour markers 
(TMs) have an important role in staging and treat-
ment of the cancer (1). Internal quality control 
(IQC) plays a significant role in the routine practice 
of clinical laboratories. The central role of IQC is to 
detect clinically important errors and evaluate re-
peatability in the analytical process. Only when 
the imprecisions of the measurement system in 
the laboratory are small enough, the staff might 
have the opportunity to get satisfactory and relia-
ble results. Clinical laboratories evaluate the im-
precisions of their own measurement systems by 
monitoring monthly (current) and long-time (cu-
mulative) coefficients of variation (CVs) of IQC 
data, and the CVs are compared with different 
quality specifications (allowable imprecision crite-
ria). The results of comparison could give the labo-
ratories directions and suggestions to make their 
performances better. There are several standards 
which could be used to evaluate the CVs of IQC, 
such as the specifications based on biological vari-
ations including the minimal, desirable, and opti-
mal allowable imprecisions, and 1/3 total allowa-
ble error (TEa) and 1/4 TEa. As the evaluation 
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standards of the external quality assessment (EQA) 
in China were often set as TEa, the 1/3 TEa and 1/4 
TEa could be calculated easily for each analyte 
whose TEa has been known before. Clinical labora-
tories in China have always used 1/3 TEa and 1/4 
TEa to evaluate the imprecisions of their measure-
ment systems (2). Although the 1/3 TEa and 1/4 
TEa were convenient and easy to use, considera-
tion of combining allowable imprecision specifica-
tions based on biological variations and different 
clinical requirements might be more suitable for 
all kinds of clinical laboratories regardless of size 
and conditions, which had gained a consensus 
recommendation among experts and clinical lab-
oratories staff in recent years (3). From each TMs 
EQA program participating laboratory in China 
two types of CVs, the control rules, methods, in-
struments, reagents, calibrators and averages of 6 
TMs (alpha-fetoprotein (AFP), carcinoembryonic 
antigen (CEA), total prostate specific antigen (PSA), 
cancer antigen 125 (CA125), cancer antigen 15-3 
(CA15-3) and cancer antigen 19-9 (CA19-9)) IQC 
materials were collected. Then all the acquired CVs 
of IQC were analysed per 5 imprecision specifica-
tions (minimal, desirable, and optimal allowable 
imprecision based on biological variations, and 
1/3 TEa and 1/4 TEa). After that we could get an 
overview of measurement imprecision for these 6 
TMs in clinical laboratories in China. So far, IQC was 
one of the best ways to evaluate the imprecision 
of routine laboratory work in simple, convenient 
and effective way. There are some different meas-
urement systems used to test TMs in China. We 
wanted to evaluate and compare their perfor-
mances, and gain insight on which one is used the 
most and which one had the smallest imprecision.
Materials and methods
Materials
Clinical laboratories participating in the 2016 TMs 
EQA programme, organized by the National Center 
for Clinical Laboratories (NCCL) which had been the 
official EQA programs provider in China for more 
than 20 years, received survey questionnaires. A to-
tal of 1821 laboratories received the questionnaire 
and 1628 answered it (89%). The TMs included were: 
AFP, CEA, PSA, CA125, CA15-3 and CA19-9.
Methods
Our study was a current status survey. In June 
2016, all the information was collected via a web-
site developed by NCCL for conducting similar 
studies. The software (Clinet-EQA evaluation sys-
tem) and website (http://www.clinet.com.cn/) 
were created by NCCL in 1998. In the beginning, 
they were used to collect and evaluate EQA pro-
gram results. In 2016, all the participant laborato-
ries which attended 2016 TMs EQA program were 
asked to return the investigation results online by 
the website including the following information: 
performing IQC or not, principle (the method for 
concentration determination of analyte), instru-
ment, reagent (manufacturer and batch number), 
calibrator, number of IQC levels, average of each 
control (provided by laboratory staff), current CV 
(May 2016), and cumulative CV of results in-control 
(the results in-control meaning the results of IQC 
were in the acceptable ranges set by participant 
laboratories according to control rules). The CV 
was calculated and submitted by the participants. 
We collected two types of CVs: one was the CV of 
test results in-control for May 2016, the other one 
was cumulative CV of data in-control (the lot of 
IQC material unchanged). For the first one, labora-
tories needed to collect all the results of IQC in 
May 2016 which were in-control judged by their 
own control rules, which meant they must remove 
all the results out-of-control (the results out-of-
control meaning the results of IQC were not in the 
acceptable ranges set by participant laboratories 
according to control rules) before calculation. For 
the second one, laboratories had to collect all the 
results in-control from the first to the last day until 
May 2016 with the lot of control unchanged. Then, 
the percentages of IQC CVs of the participants 
meeting the quality requirements for each TM 
were calculated per 5 imprecision criteria, which 
were the specifications based on biological varia-
tions including the minimal, desirable, and opti-
mal allowable imprecision, 1/3 TEa and 1/4 TEa, re-
spectively.
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Imprecision criteria 
Based on the performance evaluation require-
ments provided by Clinical Laboratory Improve-
ment Amendment (CLIA’ 88), our institute set 
these criteria as the TEa for these 6 TMs. The 1/3 
TEa and 1/4 TEa could be calculated and used to 
evaluate the imprecisions of the IQC of the partici-
pant laboratories in China. There were three im-
precision levels which were calculated from bio-
logical variations and used to evaluate the perfor-
mance of IQC, including: 1) minimum performance 
defined by CVA < 0.75C VI (CVA is analytical preci-
sion and CVI is the within-subject biological varia-
tion); 2) desirable performance defined by CVA < 
0.50 CVI; 3) optimum performance defined by CVA 
< 0.25 CVI. The data we used referred to the bio-
logic variation list provided by Ricos et al. (4).
Statistical analysis
Data were analysed using SPSS 13.0 (SPSS Inc, Chi-
cago, IL, USA) and Clinet-EQA evaluation system 
V1.0 (Clinet Corp, Beijing, China), designed by 
NCCL and used in the national EQA program (see 
http://www.clinet.com.cn/shop/shop). The distri-
butions of CVs of each analyte were tested by Kol-
mogorov-Smirnov test for normality. The related 
statistical parameters of CVs, including median, 
the 5th, 25th, 75th, and 95th percentile were calcu-
lated. The percentages of laboratories (total and 
divided into different subgroups by measurement 
systems) that met quality requirements of impreci-
sion were calculated.
Item Definition
Performing TMs IQC 
or not?
If your laboratory have performed TMs 
IQC, choose yes otherwise choose no
Principle The method of determination of concentration of analyte
Instrument Manufacturer and model
Reagent Manufacturer and lot
Calibrator Manufacturer and lot
Number of IQC 
controls How many levels
Average of each 
control The average in the TMs IQC chart
Current CV The CV of all TMs IQC results in-control
Long-time 
(cumulative) CV of 
results in-control
The CV of all TMs IQC results in-control 
from the first day to the last until May 
2016 with the lot unchanged
TMs - tumour markers. IQC - internal quality control. CV - 
coefficient of variation.
Table 1. The content of the tumour marker IQC survey





AFP 8 6 9 6 3
CEA 8 6 10 6 3
PSA 8 6 14 9 5
CA125 8 6 19 12 6
CA15-3 8 6 5 3 2
CA19-9 8 6 12 8 4
TMs - tumour markers. TEa - total allowable error. AFP - alpha-fetoprotein. CEA - carcinoembryonic antigen. PSA - total prostate 
specific antigen. CA125 - cancer antigen 125. CA15-3 - cancer antigen 15-3. CA19-9 – cancer antigen 19-9. *Performance according 
to biological variation. 
Table 2. Quality specifications of tumour markers based on CLIA’88 and biological variation
Results
The questionnaire was answered by 1628 labora-
tories (1628/1821, 89%). Laboratories which replied 
the survey submitted the related information and 
data for more than one TM. Table 1 shows the defi-
nitions of survey items. Table 2 shows the quality 
specifications of TMs based on CLIA’88 and biolog-
ical variations, while Table 3 shows the numbers of 
participant laboratories, medians, other percen-
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Type of CV TM N
CVs (%)
Laboratories meeting allowable imprecision 
specifications based on CLIA’88 and biological 
variation (%)
Median 5th 25th 75th 95th 1/3 TEa 1/4 TEa Minimum Desirable Optimal
Current
AFP 1358 5 2 3 7 10 88 69 91 67 24
CEA 1367 5 2 3 7 10 88 70 92 70 24
PSA 1192 5 1 3 7 11 87 69 98 91 46
CA125 1263 4 1 3 6 10 91 75 100 98 74
CA15-3 1199 5 2 3 7 11 89 69 45 20 3
CA19-9 1247 6 2 4 8 12 78 58 95 75 29
Cumulative
AFP 1243 5 2 4 7 11 84 62 88 58 14
CEA 1248 5 2 4 7 12 82 61 89 62 14
PSA 1098 6 2 4 7 12 83 61 97 88 35
CA125 1155 5 2 4 7 10 88 65 99 97 64
CA15-3 1102 6 2 4 7 12 84 59 33 10 2
CA19-9 1146 6 2 4 9 13 73 50 92 69 20
CVs - coefficient of variations reported by participating laboratories. TM - tumour marker. TEa - total allowable error. N – number of 
participating laboratories. 5th, 25th, 75th, 95th – percentiles. AFP - alpha-fetoprotein. CEA - carcinoembryonic antigen. PSA - total 
prostate specific antigen. CA125 - cancer antigen 125. CA15-3 - cancer antigen 15-3. CA19-9 – cancer antigen 19-9.
Table 3. Survey results for the participating laboratories
tiles of two types of CVs, and the percentages of 
laboratories meeting quality requirements. Table 4 
shows the principles and systems used for testing 
TMs; Table 5 and 6 show the percentages of two 
types of CVs of different principles and systems 
meeting different imprecision criteria. These two 
types of CVs were shown abnormal distributions 
accessed by normality test.
In Table 3 current CVs are listed and 5 out of 6 ana-
lytes (except CA19-9) showed relatively smaller 
CVs compared with CA19-9. The percentages of 
laboratories whose CVs were smaller than 1/3 TEa 
specification for these TMs were all above 87% 
(from 87% for PSA to 91% for CA125), while the 
percentages varied markedly (from 3% for CA15-3 
to 74% for CA125) when the optimal allowable im-
precision specification was used. Although current 
CVs of CA19-9 were larger than other TMs, the per-
centage of laboratories whose CVs were smaller 
than 1/3 TEa specification was close to 80% 
(974/1247). The percentages of laboratories whose 
CVs met imprecision criteria based on biological 
variations for CA15-3 were significantly smaller 
than other TMs. For the cumulative CVs, as the cur-
rent ones, 5 TMs got relatively smaller CVs com-
pared with CA19-9. The percentiles of current CVs 
of laboratories were lower than cumulative CVs.
A proportion of 76% laboratories (1240/1628) re-
ported their principles and systems used. Table 4 
shows the principles, systems, and numbers of 
laboratories of each system as well as the manu-
facturer’s information. We categorized the princi-
ples of assay into 6 groups including: 1) acridine 
ester direct chemiluminescence; 2) microparticle 
chemiluminescence-3-(2’-spiroadamantane)-
4-methoxy-4-(3”-phosphoryloxy)-phenyl-1,2-diox-
etanes (AMPPD) labelling; 3) luminol/isoluminol 
chemiluminescence; 4) flow fluorescence immu-
noassay; 5) electrochemiluminescence (ECL); 6) en-
zyme immunochemical luminescence. The ECL 
was the most used of all the 6 principles. About 
45% of laboratories used ECL principle (Group 5) to 
test TMs. The principles used fewest were flow flu-
orescence immunoassay (Group 4) and enzyme 
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Group Assay principle System (manufacturer, city, country)
Participating laboratories, N
AFP CEA PSA CA125 CA15-3 CA19-9
1 Acridine ester direct chemiluminescence
Abbott Architect i2000SR/i2000/i1000SR 
(Abbott,Chicago, USA) 224 223 213 203 197 183
Siemens Centaur /XP (Siemens, Berlin, Germany) 122 125 73 113 106 112





Beckman Access/Access 2 (Beckman, Brea, USA) 27 27 25 26 24 23
Beckman DXI 600, DXI 800 (Beckman, Brea, USA) 139 138 117 117 114 119
Shenzhen Mindray CL-2000i (Shenzhen, 
Guangdong, China) 26 26 24 24 22 23
3 Luminol/Isoluminol chemiluminescence
DiaSorin S.p.A LIAISON (DiaSorin, Saluggia, Italia) 17 19 15 15 15 16
Maglumi 600/1000/1000plus/2000/2000plus/30
00/4000 (Shenzhen, Guangdong, China) 35 36 32 34 33 35
4 Flow fluorescence immunoassay Luminex100, 200 (Luminex, Austin, USA) 30 31 28 31 27 29
5 ECL
Roche Cobas e411 (Roche, Basel, Switzerland) 84 85 79 84 81 85
Roche Cobas e601/e602 (Roche, Basel, 
Switzerland) 410 415 383 404 384 406
Roche Modular E170/PP/P800 (Roche, Basel, 
Switzerland) 60 61 55 58 57 61
6 Enzyme immuno- chemiluminescence AutoLumo A2000 (Zhengzhou, Henan, China) 31 32 25 27 26 26
TMs - tumour markers. ECL – electrochemiluminescence. AFP - alpha-fetoprotein. CEA - carcinoembryonic antigen. PSA - total 
prostate specific antigen. CA125 - cancer antigen 125. CA15-3 - cancer antigen 15-3. CA19-9 – cancer antigen 19-9. AMPPD - 
3-(2’-spiroadamantane)-4-methoxy-4-(3”-phosphoryloxy)-phenyl-1,2-dioxetanes.
Table 4. Principles and systems for tumour markers assays
immunochemical luminescence (Group 6), the 
percentages were all about 3%. Coincidentally, the 
percentages of group 5 meeting the specifications 
were the highest while group 4 and 6 were the 
lowest.
Table 5 and table 6 show the information about 
the percentages of current CVs and cumulative 
CVs meeting different imprecision criteria for all 
groups. The results of group 5 were better com-
pared to others. Almost all the assay principles 
could archieve more than 80% of laboratories 
meeting the minimum imprecision criterion based 
on biological variation except CA15-3. However, 
judging by the strictest specification based on bio-
logical variations (i.e. the optimal), almost all the 
percentages were lower than 50%. The results of 
group 6 were not so encouraging for almost all the 
imprecision criteria.
Discussion
The results of our survey suggest that there were 
remarkable variations for the TMs IQC in China, in-
cluding manufacturer, principle and imprecision. 
Harmonized control rules with defined ranges of 
imprecisions were not defined in China. Some 
studies only kept their focus on the performances 
of different test systems (5). Compared with 
Bertsch et al. the range of CVs for CA19-9 IQC was 
much wider in our study. The performances should 
be improved later (5). Consequently, the lack of 
standards might lead to many problems in daily 
monitoring of imprecision. The wide ranges of cur-
rent and cumulative CVs of TM IQC materials re-
ported by the participant laboratories, which var-
ied dramatically (from less than 1% to more than 
50%) also shocked us.
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TM Principle of assay (group)
Allowable imprecision specifications based on CLIA’88 and biological variation (%)
1/3 TEa 1/4 TEa Minimum Desirable Optimal
AFP
1 86 72 70 89 29
2 86 64 63 90 15
3 79 63 62 83 12
4 77 27 23 87 3
5 95 76 73 97 28
6 52 32 29 65 6
CEA
1 84 67 67 89 14
2 89 73 74 92 19
3 73 49 49 82 5
4 87 42 42 97 6
5 95 79 79 97 37
6 56 41 41 72 13
PSA
1 84 69 86 98 41
2 87 73 91 98 50
3 79 51 89 98 19
4 86 50 96 100 4
5 94 74 97 99 57
6 56 32 64 92 12
CA125
1 92 83 98 100 82
2 89 79 98 100 78
3 82 59 98 100 59
4 74 23 94 100 23
5 96 79 100 100 78
6 59 37 78 100 37
CA15-3
1 87 69 14 45 3
2 89 69 11 37 3
3 75 44 8 27 6
4 78 33 0 7 0
5 95 76 29 56 3
6 54 23 8 12 8
CA19-9
1 65 36 59 91 9
2 88 72 85 95 25
3 71 43 65 96 27
4 69 17 62 97 3
5 88 74 86 99 45
6 27 23 27 77 12
TM - tumour marker. Group 1 – acridine-ester direct chemiluminescence. Group 2 - microparticle chemiluminescence. Group 3 - 
luminol/isoluminol chemiluminescence. Group 4 - flow fluorescence immunoassay. Group 5 – electrochemiluminescence. Group 6 
- enzyme immunochemical luminescence. TEa - total allowable error. AFP - alpha-fetoprotein. CEA - carcinoembryonic antigen. PSA 
- total prostate specific antigen. CA125 - cancer antigen 125. CA15-3 - cancer antigen 15-3. CA19-9 – cancer antigen 19-9.
Table 5. Proportions of laboratories meeting different imprecision specifications with current coefficients of variation 
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TM Principle of assay (group)
Allowable imprecision specifications based on CLIA’88 and biological variation (%)
1/3 TEa 1/4 TEa Minimum Desirable Optimal
AFP
1 82 64 60 85 19
2 77 57 49 84 7
3 72 46 41 76 9
4 73 20 17 90 0
5 91 69 67 95 16
6 52 30 30 63 7
CEA
1 74 54 55 83 6
2 84 60 62 88 8
3 57 37 37 69 12
4 84 26 29 94 3
5 92 72 73 96 24
6 56 30 30 78 11
PSA
1 79 57 84 97 27
2 80 61 85 97 31
3 72 49 81 98 30
4 86 29 93 96 4
5 91 68 93 97 46
6 59 36 64 95 14
CA125
1 86 63 97 99 63
2 85 67 96 99 63
3 73 40 98 100 40
4 74 16 94 97 16
5 94 74 99 100 73
6 61 35 78 100 35
CA15-3
1 78 56 5 29 2
2 79 52 5 23 1
3 64 36 9 18 7
4 96 15 0 0 0
5 91 69 15 44 2
6 55 14 9 9 9
CA19-9
1 53 26 48 85 7
2 83 54 78 94 15
3 64 38 57 85 26
4 76 14 62 93 3
5 84 66 82 97 30
6 32 23 32 77 9
TM - tumour marker. Group 1 – acridine-ester direct chemiluminescence. Group 2 - microparticle chemiluminescence. Group 3 - 
luminol/isoluminol chemiluminescence. Group 4 - flow fluorescence immunoassay. Group 5 – electrochemiluminescence. Group 
6 - enzyme immunochemical luminescence. TEa - total allowable error. AFP - alpha-fetoprotein. CEA - carcinoembryonic antigen. 
PSA - total prostate specific antigen. CA125 - cancer antigen 125. CA15-3 - cancer antigen 15-3. CA19-9 – cancer antigen 19-9.
Table 6. Proportions of laboratories meeting different imprecision specifications with cumulative coefficients of variation 
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Cancer antigen 19-9 had the largest CVs of all TMs, 
which presented that Chinese laboratories should 
pay more attention to this analyte. The cumulative 
CVs were slightly larger than current CVs, which 
might reveal that the long-time repeatability was 
not as good as short-term one. We might provide 
some suggestions such as: 1) about 80% Chinese 
clinical laboratories with better medical resource 
could meet the 1/3 TEa criteria which could be 
considered as evaluation standard for IQC pro-
gram; 2) the cumulative CVs were larger than cur-
rent CVs, which means that more attention should 
be paid to long-time repeatability. The ideal situa-
tion should be, the longer a lot of IQC material 
tested, the smaller CVs should be. That was be-
cause with the increasing of test times, the results 
and variation should be more and more stable, if 
the test system had been stable all the time. The 
long-time stability of measurement system should 
be improved in China.
Cancer antigen 15-3 had the strictest specification 
based on biological variation, which made the 
percentages of laboratories meeting criteria much 
lower than other TMs. So we should know that 1/3 
TEa should be used carefully because it was much 
bigger than the specifications based on biological 
variation. We might pay more effort on finding a 
better and more reasonable IQC evaluation criteri-
on which could better match the performance of 
test system and biological variations in the future.
The ECL method had the highest CVs of TMs IQC 
meeting the evaluation specifications, which 
might be one of the reasons why most laborato-
ries chose ECL method. A study also verified that 
the ECL method and Roche test system could 
achieve a good performance in TMs measurement 
(6). Compared with other analytes in Chinese Profi-
ciency testing (PT) panel, creating national evalua-
tion specifications for imprecision of TMs was 
needed to improve the quality of measurement 
(7,8).
Clinical laboratories in this study were located in 
different areas of China and could be considered 
as representatives of Chinese clinical laboratories 
with better medical resources and more concern 
on their performance than those who did not par-
ticipate to TMs EQA program or return the ques-
tionnaires. Most of the clinical laboratories partici-
pating in these kinds of surveys were mostly first-
class hospitals in China (9,10).
There were still some limitations in our study. Hu-
man epidermal growth factor receptor 2 (HER2) 
was a TM which was newer than these 6 TMs and it 
had been in focus in recent years. There is another 
way to perform IQC for HER2 and we should keep 
up with the time (11). Another study reported that 
lyophilized QC materials for TMs were insufficient-
ly stable for use in quality control among clinical 
laboratories (12). This might result in cumulative 
CVs bigger than current ones, which might be 
studied in the further studies. In Lent et al. study, 
they made a conclusion that treatment errors in 
association with PSA determinations could there-
fore be uniformly and plausibly assessed using ob-
jective criteria and could thus be avoided (13). IQC 
was an effective way to decrease errors occur-
rence. We might combine IQC to evaluate treat-
ment errors occurrence rate to study the relation-
ship between them.
In conclusion, the performance of laboratories for 
TMs IQC has yet to be improved. On the basis of 
the obtained results, 1/3 TEa would be realistic 
and attainable quality specification for TMs IQC for 
clinical laboratories in China.
Acknowledgments
We thank all laboratories and institutions that par-
ticipated in the TMs EQA programme organized by 
NCCL. We also appreciate Clinet website (www.cli-
net.com.cn) that provided computer technology 
support to establish the website for similar studies 
and relevant services.
Potential conflict of interest
None declared. 
https://doi.org/10.11613/BM.2018.020702 Biochem Med (Zagreb) 2018;28(2):020702 
  9
Wang W. et al. IQC for TMs in clinical laboratories in China
References
 1. Koepke JA. Molecular marker test standardization. Can-
cer 1992;69:1578-81. https://doi. org/10.1002/1097-
0142(19920315)69:6+<1578::AIDCNCR2820691312>3.0.
CO;2-K
 2. Zeng R, Wang W, Zhao HJ, Fei Y, Wang ZG. National Survey 
on Internal Quality Control for HbA1c Analytical Instruments 
in 331 Hospital Laboratories of China. Clin Lab 2015;61:453-
60. https://doi.org/10.7754/Clin.Lab.2014.141123
 3. Skitek M. Acceptability limits based on biology goals in hae-
matology EQAS. Accred Qual Assur 2005;10:112–5. https://
doi.org/10.1007/s00769-004-0889-8
 4. Ricos C, Alvarez V, Cavas F, Garcia-Lario JV, Hernandez A, Ji-
menez CV, et al. Desirable specifications for total error, im-
precision, and bias, derived from intra- and inter-individual 
biologic variation. Available at: http://www.westgard.com/
biodatabase1.htm. Accessed January 5th 2018.
 5. Bertsch T, Aschenneller C, Bewarder N, Beyrau R, Herr-
mann BL, Jansen E, et al. European proficiency study with 
control serum for the tumor marker CA 19-9 measured on 
different test systems. Clin Lab 2013;59:185-92. https://doi.
org/10.7754/Clin.Lab.2012.111112
 6. Dolci A, Scapellato L, Mozzi R, Panteghini M. Imprecisi-
on of tumour biomarker measurements on Roche Modular 
E170 platform fulfills desirable goals derived from biologi-
cal variation. Ann Clin Biochem 2010;47:171-3. https://doi.
org/10.1258/acb.2009.009228
 7. Zhong K, Zhao Y, Xiao YL, Wang W, He FL, Wang ZG. 8-year 
review of laboratory performance on blood lead level exter-
nal quality assessment surveys 2006–2013 in China: conti-
nual improvement. Accred Qual Assur 2015;20:25-8. https://
doi.org/10.1007/s00769-014-1097-9
 8. Zhong K, Wang W, He FL, Wang ZG. Neona-
tal screening external quality assessment in China, 
2014. J Med Screen 2015;22:175-81. https://doi.
org/10.1177/0969141315592924
 9. Zeng R, Wang W, Wang ZG. National survey on critical va-
lues notification of 599 institutions in China. Clin Chem Lab 
Med 2013;51:2099-107. https://doi.org/10.1515/cclm-2013-
0183
10. Zhong K, Wang W, He FL, Wang ZG. The status of neonatal 
screening in China, 2013. J Med Screening 2016;23:59-61. 
https://doi.org/10.1177/0969141315597715
11. Ngo C, Laé M, Ratour J, Hamel F, Taris C, Caly M, et al. In-
ternal quality control on HER2 status determination in 
breast cancers: Experience of a cancer center. Bull Can-
cer 2017;104:608-17. https://doi.org/10.1016/j.bul-
can.2017.05.002
12. Ahn S, Park J, Kim YR, Kim JH, Kim HS. Stability of lyophili-
zed pooled sera as quality control materials for tumor mar-
ker assays in external quality assessment. Clin Chim Acta 
2017;471:233-42. https://doi.org/10.1016/j.cca.2017.05.035
13. Lent V, Baumbusch F, Weber B. Criteria for errors in prostate-
specific antigen diagnostics. Urologe A 2012;51:1558-61. (in 
German) https://doi.org/10.1007/s00120-012-2968-5
